Gland Pharma announces investment, director resignation, and new director appointment
Gland Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Approved USD 21 million investment in wholly-owned subsidiary Gland Pharma USA Inc. to acquire 60% stake in Novelstar Pharma Inc. by October 31, 2026
- Mr. Wenjie Zhang resigned as Non-Executive Non-Independent Director effective October 1, 2026, due to pre-occupations
- Appointed Mr. Xingli Wang as Additional Director (Non-Executive Non-Independent) effective October 1, 2026; member approval to be obtained via postal ballot and e-voting
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Gland Pharma
- Capex / expansionNotableGland Pharma and Neuland Laboratories announce strategic sterile API manufacturing partnership
Other acquisition / merger filings this fortnight
- Acquisition / mergerZydus LifesciencesZydus Lifesciences completes subscription and joint venture with Zydus Sunshine
- Abans Financial Services announces CEO resignation, new director appointment, and subsidiary incorporation
- Alivus Life Sciences acquires 65.01% stake in IQGEN-X Pharma
- Indo Borax reports H1FY27 consolidated operating income up 16.0% to Rs 129.29 crore
- Manoj Agrawal Acquires 1.00 Crore Shares in Cubical Financial Services Limited
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.